Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study

Area of Science:

• Psychiatry
• Pharmacology

Background:

• Schizophrenia is a complex psychiatric disorder requiring effective treatment.
• Haloperidol is a commonly used antipsychotic, but newer agents are being investigated.

Purpose of the Study:

• To compare the efficacy and side effect profiles of pimozide and haloperidol in acutely hospitalized schizophrenic patients.
• To assess the impact of these treatments on specific symptom clusters.

Main Methods:

• A double-blind study involving 30 schizophrenic patients.
• Patients received either haloperidol (40-60 mg/day) or pimozide (40-60 mg/day) for 30 days.
• Clinical response was assessed using Global Clinical Impression and the Brief Psychiatric Rating Scale (BPRS).

Main Results:

• Both haloperidol and pimozide groups showed significant reductions in global BPRS scores.
• Pimozide treatment led to significant improvements in affective bluntedness and anergia, unlike haloperidol.
• Extrapyramidal side effects were more frequent with pimozide, necessitating more anticholinergic use.
• No clear correlation was found between drug serum levels and clinical outcomes.

Conclusions:

• Pimozide (40-60 mg/day) demonstrates potent antipsychotic efficacy comparable to haloperidol.
• Pimozide is associated with a higher incidence of extrapyramidal side effects compared to haloperidol.
• Further research may explore strategies to mitigate side effects with pimozide treatment.